Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0011849 (
diabetes
)
277,896
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
To verify the hypothesis that borderline
diabetes
may increase the risk of dementia and Alzheimer's disease, a community-based cohort of 1,173 dementia- and
diabetes
-free individuals aged >or=75 years was longitudinally examined three times to detect patients with dementia and Alzheimer's disease (Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition criteria).
Borderline diabetes
was defined as a random plasma glucose level of 7.8-11.0 mmol/l. Data were analyzed using Cox proportional hazards models. During the 9-year follow-up, 397 subjects developed dementia, including 307 Alzheimer's cases. At baseline, 47 subjects were identified with borderline
diabetes
.
Borderline diabetes
was associated with adjusted hazard ratios (95% CIs) of 1.67 (1.04-2.67) for dementia and 1.77 (1.06-2.97) for Alzheimer's disease; the significant associations were present after additional adjustment for future development of
diabetes
. Stratified analysis suggested a significant association between borderline
diabetes
and Alzheimer's disease only among noncarriers of APOE epsilon4 allele. There was an interaction between borderline
diabetes
and severe systolic hypertension on the risk of Alzheimer's disease (P = 0.04). We conclude that borderline
diabetes
is associated with increased risks of dementia and Alzheimer's disease; the risk effect is independent of the future development of
diabetes
.
Borderline diabetes
may interact with severe systolic hypertension to multiply the risk of Alzheimer's disease.
Diabetes
2007 Jan
PMID:The effect of borderline diabetes on the risk of dementia and Alzheimer's disease. 1719 84